|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Burnell M et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006;Abstract 53.
Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract
Gunnarsdottir K et al. CEF is superior to CMF for tumors with topoisomerase II gene alterations: A STEPP (subpopulation treatment effect pattern plot) analysis on Danish breast cancer cooperative group study 89D. San Antonio Breast Cancer Symposium 2006;Abstract 1023.
Joensuu H et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer Trial. San Antonio Breast Cancer Symposium 2005;Abstract 2.
Johnson PH et al. Nuclear staining of topoisomerase II (topo II) may predict response to anthracycline but not taxane-based neoadjuvant chemotherapy regimens. San Antonio Breast Cancer Symposium 2006;Abstract 1024.
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract
O’Malley FP et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). San Antonio Breast Cancer Symposium 2006;Abstract 38.
Pegram M et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 301.
Pegram MD et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004;88(Suppl 1):124. Abstract 3039.
Perez E et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (Herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2005;Abstract 1.
Smith I et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: A randomized controlled trial. Lancet 2007;369(9555):29-36. Abstract
 |
 |
